Effects of chromatin-modifying agents on CD34⁺ cells from patients with idiopathic myelofibrosis

Medicine and Dentistry

• Cells 100%
• Myeloid metaplasia 90%
• Decitabine 54%
• Trichostatin A 45%
• Therapeutic Procedure 45%
• Patient 45%
• Chromatin 18%
• Upregulation 9%
• Cell Proliferation 9%
• Combination Therapy 9%
• Programmed Cell Death 9%
• Epigenomics 9%
• Chromosome Aberration 9%
• Mobilization 9%
• Stromal Cell Derived Factor 1 9%
• Histone Deacetylase Inhibitor 9%
• Stem Cell 9%
• DNA Methyltransferase Inhibitor 9%
• Gene 9%
• Chemokine Receptor CXCR4 9%
• Differentiation 9%

Biochemistry, Genetics and Molecular Biology

• CD34 81%
• Trichostatin A 45%
• Deoxycytidine 45%
• Reduction (Chemistry) 36%
• Chromatin 18%
• CXCR4 18%
• Janus Kinase 18%
• Apoptosis 9%
• Mutation 9%
• Nested Gene 9%
• Upregulation 9%
• Wild Type 9%
• Cell Proliferation 9%
• Gene Mutation 9%
• Chromosomal Abnormalities 9%
• Decitabine 9%
• DNA Methyltransferase 9%
• Histone Deacetylase 9%
• Epigenetics 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Myeloid metaplasia 90%
• Decitabine 54%
• Trichostatin A 45%
• Histone Deacetylase Inhibitor 9%
• Chromosome Aberration 9%
• DNA Methyltransferase Inhibitor 9%
• Stromal Cell Derived Factor 1 9%
• Chemokine Receptor CXCR4 9%